The target is a leukemia drug developer. The real objective is something larger: time, diversification, and a more believable post-Keytruda growth story.
Merck’s agreement to buy Terns Pharmaceuticals for $53 a share, or about $6.7 billion in equity value, looks at first like a familiar big-pharma move: pay up for a promising oncology asset before the next data inflection point. But that reading is too narrow. This is not mainly a story about one chronic myeloid leukemia program. It is a story about what happens when one of the most successful drugs in modern pharma becomes too large to comfortably depend on.
